Back to results
US 2003/0165477 A1Published application
Poxvirus with targeted infection specificity
AssigneeTransgene S.A.
InventorsJean-Marc Balloul, Stephane Paul, Michel Geist
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeTransgene S.A.
InventorsJean-Marc Balloul, Stephane Paul, Michel Geist
Estimating the term…
The present invention concerns a poxviral particle having a targeted infection specificity conferred by an heterologous ligand moiety present at the surface of said poxviral particle and capable of specifically recognizing and binding to an anti-ligand molecule localized at the surface of target cells. The present invention further relates to a vector comprising a nucleotide sequence encoding a chimeric polypeptide including such an heterologous ligand moiety and all or part of a natural poxviral surface polypeptide. The present invention additionally concerns compositions comprising said poxviral particle or said vector as well as their use for therapeutic and prophylactic purposes. The invention is of very special interest in gene therapy applications, in particular in preventing or treating cancer in mammals.
A poxviral particle having a targeted infection specificity towards target cells wherein said particle infects preferably said target cells and wherein said specificity is conferred by at least one heterologous ligand moiety which is localized at the surface of said poxviral particle and which is capable of binding an anti-ligand molecule localized at the surface of said target cells, with the proviso that when said poxviral particle is an EEV vaccinia virus particle said ligand is not an antibody directed to ErbB-2.
Dependencies are inferred from the claim text.